Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors
Vertex Pharmaceuticals Inc. closed 19.80% below its 52-week high of $519.88, which the company reached on November 8th.
Bank of America Securities Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research ...
MarketBeat on MSN9h
Vertex's Pain Drug: Big Pharma's Next Major Success?
Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Vertex Pharmaceuticals Inc. closed 18.39% short of its 52-week high of $519.88, which the company reached on November 8th.
Should You Buy Vertex Pharmaceuticals Stock Hand Over Fist Before Jan. 30?
Vertex Pharmaceuticals ( VRTX 3.06%) might be one of those special cases. Should you buy Vertex stock hand over fist before ...
Reuters21h
Healthcare & Pharmaceuticals
UnitedHealth Group's headquarters building is seen in Minnetonka, Minnesota, U.S. in this handout picture taken in 2019. UnitedHealth Group/Handout via REUTERS/File Photo Analysts and investors ...
pharmaphorum21h
First CRISPR drug Casgevy gets swift second approval
The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...
pharmaphorum21h
Opportunity costs of gene therapies. Where do we go from here?
All the major pharma companies, including AstraZeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Novo Nordisk, Otsuka Pharmaceuticals, Roche, and Sanofi, have invested in this area.